19 June 2013
Keywords: encysive, thelin, study, meets, endpoints, phase, iii
Article | 21 February 2005
A Phase III, 18-week, double-blind safety and efficacy clinical trial of US firm Encysive's Thelin (sitaxsentan sodium) for pulmonary arterial
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 February 2005
© 2013 thepharmaletter.com